Global Genome Editing Market, By Technology (CRISPR, TALEN, ZFN, ANTISENSE, Other Technologies), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery and Development, Other Applications), Product and Service (Reagents and Consumables), End User (Pharmaceutical and Biopharmaceutical Industry, Biotechnology Industry, Academic Institutions, CROs, Government Research Organizations, Others), Method (Ex-Vivo, In-Vivo) – Industry Trends and Forecast to 2030.
Genome Editing Market Analysis and Size
Genome editing is a relatively new technique for changing specific DNA sequences. It has become common practice in fundamental biomedical research to examine gene function by modifying genomes using the bacterial immune system, a potent tool for genome editing. This technology is increasingly used in studying and treating human diseases by altering human blood cells injected into the body to cure various diseases, such as cystic fibrosis, cancer, and AIDS.
Data Bridge Market Research analyses that the global genome editing market, which was USD 5,512.13 million in 2022, is expected to reach USD 18,400.23 million by 2030 and is expected to undergo a CAGR of 17.2% during the forecast period of 2023 to 2030. "CRISPR" dominates the technology segment of the global genome editing market due to the rising demand for genome editing. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Genome Editing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Technology (CRISPR, TALEN, ZFN, ANTISENSE, Other Technologies), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery and Development, Other Applications), Product and Service (Reagents and Consumables), End User (Pharmaceutical and Biopharmaceutical Industry, Biotechnology Industry, Academic Institutions, CROs, Government Research Organizations, Others), Method (Ex-Vivo, In-Vivo)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina, and Rest of South America as part of South America
|
|
Market Players Covered
|
Merck KGaA (Germany), GenScript (China), Sangamo Therapeutics (U.S.), Lonza (Switzerland), Editas Medicine (U.S.), CRISPR Therapeutics (Switzerland), Tecan Trading AG (Switzerland), Precision Biosciences (U.S.), PerkinElmer Inc. (U.S.), Cellectis S.A (France), Genome Medical, Inc. (U.S.), BioMed Central Ltd (U.K.), Aevi Genomic Medicine, Inc. (Israel), Congenica Ltd. (U.K.), Deep Genomics (Canada), Editas Medicine (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.) QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), and Bio-Rad Laboratories, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Genome editing is a technique for precisely altering an organism's or cell's DNA. It is used to alter any organism's genome. It uses a special kind of enzyme called an "engineered nuclease" that makes a precise cut in the genome. A specific region of the DNA is cut, and the cell automatically heals the damage. It has uses in various fields, including agriculture, biotechnology, medicines, and mutation. The prevalence of chronic and infectious diseases will probably increase, broadening the application of genome editing.
Global Genome Editing Market Dynamics
Drivers
- Developments in Genome Editing
The recent advancements in this area have significantly improved genome editing capabilities, allowing the change of interesting gene sequences in several cell types and model species. Genome engineering has evolved into a potentially game-changing diagnostic tool for oncology studies. Huge research organizations, such as government and academic research institutions, used genome engineering. The rapid advancement of gene editing technology is the main force behind this radical shift away from academics and toward clinical and diagnostic laboratories.
- Increased Application Areas of Genomics
Application areas for genomics include drug research, agribusiness, veterinary sciences, forensics, and the identification of human genetic abnormalities. The use of genomics in forensic studies has dramatically risen, largely to products provided by Illumina (U.S.), which were created especially for the field. Earlier, DNA analysis was utilized for fingerprint profiling. NGS aids in crime scene analysis and makes it possible to recover more information from a trace or damaged DNA sample, which is expected to drive market growth.
- Advancements in CRISPR-Cas9 Technology
The rapid evolution of the CRISPR-Cas9 genome editing technology has revolutionized the field. CRISPR-based techniques are more accessible, cost-effective, and precise, opening up new possibilities for genome editing applications. Companies invest in research to further refine CRISPR-based tools and expand their applications.
Opportunities
- Environmental Conservation by Enabling the Modification of Organisms
Genome editing can play a role in environmental conservation by enabling the modification of organisms to address ecological challenges, such as invasive species or habitat restoration. Environmental organizations and researchers explore genome editing for conservation efforts to capitalize on this opportunity.
- Gene Therapy Advancements
The development of gene therapy using genome editing techniques presents a significant opportunity. Gene therapies can potentially cure genetic diseases by precisely modifying faulty genes. Biotech firms and research institutions invest in clinical trials and therapeutic development to seize this opportunity.
Restraint/Challenge
- Ethical and Regulatory Challenges
One of the primary restraints in the global genome editing market is the ethical and regulatory complexity of editing the human germline. The potential for unintended consequences and the need for strict ethical guidelines create barriers to certain applications.
This global genome editing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global genome editing market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2021, Precision BioSciences, Inc. and Eli Lilly partnered to create potential in-vivo therapies for genetic illnesses using the latter company's unique ARCUS genome editing platform
Global Genome Editing Market Scope
The global genome editing market is segmented on the basis of technology, application, product and service, method, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Technology
- CRISPR
- TALEN
- ZFN
- ANTISENSE
- Other Technologies
Application
- Cell Line Engineering
- Genetic Engineering
- Diagnostic Applications
- Drug Discovery and Development
- Other Applications
Product and Service
- Reagents
- Consumables
End User
- Pharmaceutical and Biopharmaceutical Industry
- Biotechnology Industry
- Academic Institutions
- CROs
- Government Research Organizations
- Others
Method
- Ex-Vivo
- In-Vivo
Global Genome Editing Market Regional Analysis/Insights
The global genome editing market is analyzed, and market size insights and trends are provided by country, technology, application, product and service, method, and end user, as referenced above.
The countries covered in the global genome editing market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina, and rest of South America as part of South America.
North America dominates the global genome editing market due to the increased expenditure for research and development proficiencies, increasing government initiatives, and improved healthcare infrastructure in various countries.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 owing to the increasing government expenditure on the healthcare sector and rising technological advancements and initiatives by the government.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global genome editing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global genome editing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global genome editing market. The data is available for historic period 2011-2021.
Competitive Landscape and Global Genome Editing Market Share Analysis
The global genome editing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global genome editing market are:
- Merck KGaA (Germany)
- GenScript (China)
- Sangamo Therapeutics (U.S.)
- Lonza (Switzerland)
- Editas Medicine (U.S.)
- CRISPR Therapeutics (Switzerland)
- Tecan Trading AG (Switzerland)
- Precision Biosciences (U.S.)
- PerkinElmer Inc. (U.S.)
- Cellectis S.A (France)
- Genome Medical, Inc. (U.S.)
- BioMed Central Ltd (U.K.)
- Aevi Genomic Medicine, Inc. (Israel)
- Congenica Ltd. (U.K.)
- Deep Genomics (Canada)
- Editas Medicine (U.S.)
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN N.V. (Netherlands)
- Agilent Technologies, Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
SKU-